News & Views

Telix today announces it has entered into an agreement to acquire Lightpoint Medical and its SENSEI® radio-guided surgery business. Lightpoint Medical is a United Kingdom-based medical device company specialising in the intra-operative detection of targeted radiopharmaceuticals.

Telix today provides an outline agenda for the Company’s briefing session for shareholders to be held on Wednesday, June 21, 2023, at The Yale Club in New York City, from 8.30am EDT and via live webcast (10.30pm AEST). The briefing session will provide an opportunity for shareholders to hear from the Company in relation to its recent market disclosures and will focus on:

Telix today announces that the first patient has been dosed in a global Phase II study of the Company’s carbonic anhydrase- (CAIX)-targeting PET/CT[1] imaging agent TLX250-CDx (89Zr-DFO-girentuximab), exploring this potential target across a broad range of cancer indications.

Telix has today been recognised as Australia’s highest achieving company for international growth in the Australian Financial Review’s Fast Global list. Fast Global celebrates Australian companies that are delivering real commercial growth in international markets, calculated on growth in revenue generated outside of Australia over the past three years. to officially open Telix Manufacturing Solutions, the Company’s radiopharmaceutical production facility located in Brussels South (Seneffe), in the Wallonia region of Belgium. Located in the heart of Belgium’s ‘Radiopharma Valley’, the 2,800 square metre facility is one of Europe’s largest radiopharmaceutical production facilities. It will serve as the Company’s primary manufacturing site for radioisotopes and commercial and clinical products for patients in the Europe Middle East and Africa (EMEA) region and beyond. Radiopharmaceuticals use targeting agents (small molecules or antibodies) to deliver targeted radiation to cancer cells, regardless of where the cancer is in the body. These agents can be used for imaging (diagnosis) or therapy. Often referred to as “theranostics”, this approach has the potential to better inform treatment decisions and deliver personalised therapy for patients. The presentation will take place on Wednesday June 7 from 12.30pm – 12.55pm EDT (2.30am – 2.55am AEST, June 8). A live webcast of the presentation will be available at the following link: https://wsw.com/webcast/jeff281/tlx/1727440 The webcast will be accessible on demand on the Telix website following the event. Institutional investors, analysts and company guests are cordially invited to attend the session, which will feature an overview of the Company's growth strategy and product pipeline for the detection and treatment of urological cancers.

Telix today welcomes Willy Borsus, Vice-President of Wallonia, Minister of Economy, Research and Innovation, Digital, Agriculture, Urban Planning and Regional Planning to officially open Telix Manufacturing Solutions, the Company’s radiopharmaceutical production facility located in Brussels South (Seneffe), in the Wallonia region of Belgium. Located in the heart of Belgium’s ‘Radiopharma Valley’, the 2,800 square metre facility is one of Europe’s largest radiopharmaceutical production facilities. It will serve as the Company’s primary manufacturing site for radioisotopes and commercial and clinical products for patients in the Europe Middle East and Africa (EMEA) region and beyond. Radiopharmaceuticals use targeting agents (small molecules or antibodies) to deliver targeted radiation to cancer cells, regardless of where the cancer is in the body. These agents can be used for imaging (diagnosis) or therapy. Often referred to as “theranostics”, this approach has the potential to better inform treatment decisions and deliver personalised therapy for patients. The presentation will take place on Wednesday June 7 from 12.30pm – 12.55pm EDT (2.30am – 2.55am AEST, June 8). A live webcast of the presentation will be available at the following link: https://wsw.com/webcast/jeff281/tlx/1727440 The webcast will be accessible on demand on the Telix website following the event. Institutional investors, analysts and company guests are cordially invited to attend the session, which will feature an overview of the Company's growth strategy and product pipeline for the detection and treatment of urological cancers.

Telix today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies Healthcare Conference being held in New York from June 7 to June 9, 2023. The presentation will take place on Wednesday June 7 from 12.30pm – 12.55pm EDT (2.30am – 2.55am AEST, June 8). A live webcast of the presentation will be available at the following link: https://wsw.com/webcast/jeff281/tlx/1727440 The webcast will be accessible on demand on the Telix website following the event. Institutional investors, analysts and company guests are cordially invited to attend the session, which will feature an overview of the Company's growth strategy and product pipeline for the detection and treatment of urological cancers.

Telix today announces it will host an education session for investors on Wednesday, June 21, 2023, at The Yale Club in New York City, from 8.30am – 12.30pm EDT.  Institutional investors, analysts and company guests are cordially invited to attend the session, which will feature an overview of the Company's growth strategy and product pipeline for the detection and treatment of urological cancers.

Join Telix in Adelaide, South Australia, for the 53rd Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine from the 26th to the 28th of May. We are pleased to support the premier event for nuclear medicine in Australia with a range of Telix investigational assets featured in presentations across the weekend.  Our team will be at booths #13 and #15 to share more on our approved PSMA-PET imaging agent for prostate cancer and the diagnostic and therapeutic solutions we are developing as part of our industry-leading theranostic pipeline.

Telix's 2023 AGM was held on Wednesday, 24th May 2023 at The Events Centre in Melbourne, Australia and online.

Telix today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, kit for the preparation of gallium Ga 68 gozetotide injection)[1] for the Phase III ARASTEP study (ClinicalTrials.gov Identifier: NCT05794906). This global study is investigating the efficacy of Bayer’s androgen receptor inhibitor (ARi) darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence who have no evidence of metastatic disease by conventional imaging and a positive PSMA-PET/CT[2] at baseline.